Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Rev. cuba. invest. bioméd ; 39(3): e391, jul.-set. 2020. tab, graf
Article in English | LILACS, CUMED | ID: biblio-1138928

ABSTRACT

Introduction: Several studies investigating blood biomarkers such as C-reactive protein (CRP) in the prognosis and mortality of stroke have not been conclusive. This may be related to the fact that age has not been taken into account for these analyses. Objective: In the present study, we evaluated the possible relationship of blood markers with the age and clinical characteristics of ischemic stroke patients. Methods: Two groups of acute ischemic stroke patients (≤ 55 years and > 55 years of age) who were paired with a control group were included. CRP, alpha 1 antitrypsin (AAT), complements C3 and C4, microalbuminura, ceruloplasmin, glucose, cholesterol, triglycerides, glutamic-piruvic transaminase (GPT), glutamic-oxalacetic transaminase (GOT), gamma glutamiltranspeptidase (GGT), creatinine, and uric acid were determined. Other clinical information, including NIH stroke scale was collected. Results: AAT, ceruloplasmin, microalbuminuria, GPT, GOT and GGT were significantly increased with respect to control subjects in both age groups. Nevertheless, CRP was increased only in patients older than 55 years. CRP and age were directly correlated in stroke patients, but not in the control group joint analysis of age and NIHSS revealed a tendency towards even higher CRP values in older patients with more severe neurological impairment. Levels of CRP increased significantly with age according to NIH score. Conclusions: Age should be considered when evaluating the usefulness of CRP and other blood biomarkers as clinical tools for predicting long or short-term neurological outcome or stroke recurrence events in ischemic stroke patients(AU)


Introducción: Los estudios sobre marcadores sanguíneos incluido la proteína C reactiva (PCR) en el pronóstico y mortalidad del ictus no han sido concluyentes, quizás porque en sus análisis no se ha tenido en cuenta la edad los pacientes. Objetivo: Evaluar la relación de los marcadores sanguíneos con la edad y características clínicas de pacientes con ictus isquémico. Métodos: Se incluyeron en el estudio 2 grupos de pacientes con ictus isquémico (( y > 55 años) quienes fueron pareados con grupos controles. Fueron determinados: PCR, alfa 1 antitripsina (AAT), complementos C3 y C4, microalbuminuria, ceruloplasmina, glucosa, colesterol, triglicéridos, transaminasa glutámico-pirúvico (TGP), transaminasa glutámico-oxalacético (TGO), gamma glutamiltranspeptidasa (GGT), creatinina, y ácido úrico. También, se recogió información clínica (escala neurológica, etiología y localización del ictus). Resultados: La AAT, ceruloplasmina, microalbuminuria, TGP, TGO y GGT aumentaron significativamente respecto al grupo control de ambos grupos de estudio. Sin embargo, la PCR se incrementó solamente en pacientes mayores de 55 años. La PCR se correlacionó directamente con la edad de los pacientes, pero no en el grupo control. A su vez, se observó una tendencia hacia el aumento de la PCR en pacientes mayores de 55 años con mayor la severidad neurológica. Los valores de PCR se incrementaron estadísticamente con la edad de acuerdo al déficit neurológico. Conclusiones: La edad debiera ser considerada en la evaluación de la utilidad de la PCR y de otros marcadores como herramientas clínicas para predecir un desenlace neurológico fatal o recurrencia de nuevos eventos en pacientes con ictus isquémico(AU)


Subject(s)
Humans , C-Reactive Protein , Polymerase Chain Reaction , Control Groups , Selection of the Waste Treatment Site , Ischemic Stroke , Age Groups , Case-Control Studies
2.
J Neurol Sci ; 363: 158-63, 2016 Apr 15.
Article in English | MEDLINE | ID: mdl-27000243

ABSTRACT

The object of this work was to explore if blood based biomarkers of brain damage could predict subclinical brain lesions and clinical outcome during follow-up in asymptomatic hypertensive patients. This was a cross-sectional study including 101 patients with essential hypertension and no clinical evidence of neurological disease and 53 healthy controls, followed by a longitudinal study of 62 hypertensive patients for an average of 33 months. Serum concentrations of two brain specific proteins (S100B and neuron specific enolase - NSE) were determined at inclusion. Fundoscopic exploration, brain MRI and echocardiographic studies were also performed. Clinical outcome at follow-up was registered: transient ischemic attack (TIA), stroke, vascular headache or migraine, cardiovascular events and death. Higher serum NSE and S100B concentrations were observed in hypertensive patients; and multiple regression analysis revealed independent associations of clinical variables and more severe white matter lesions only with NSE concentration. A panel combining two clinical variables (blood pressure>140/90 and years of hypertension>10) and serum NSE>13 µg/L predicted more severe white matter lesions with 80% sensitivity and 94.4% specificity. Higher NSE levels at inclusion were associated not only with the occurrence of vascular events related with the CNS (stroke, TIA and vascular headache), but also with an earlier presentation of these events during the follow-up period. Serum NSE concentration could be a useful biomarker to predict subclinical brain damage and future vascular events related with the CNS in hypertension. Blood based biomarkers could aid in filtering hypertensive patients with a higher risk of cerebrovascular disease for brain MRI scanning.


Subject(s)
Brain Injuries/blood , Brain Injuries/epidemiology , Hypertension/blood , Hypertension/epidemiology , Phosphopyruvate Hydratase/blood , Adult , Aged , Aged, 80 and over , Biomarkers/blood , Brain Injuries/diagnosis , Cross-Sectional Studies , Essential Hypertension , Female , Follow-Up Studies , Humans , Hypertension/diagnosis , Longitudinal Studies , Male , Middle Aged , Predictive Value of Tests , Young Adult
3.
Clin Biochem ; 48(18): 1258-63, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26210848

ABSTRACT

UNLABELLED: Huntington's disease (HD) is an autosomal dominant, progressive neurodegenerative disorder, caused by an expanded trinucleotide CAG sequence of the huntingtin (Htt) gene, which encodes a stretch of glutamines in the Htt protein. The mechanisms of neurodegeneration associated with the accumulation of Htt aggregates still remains unclear. OBJECTIVES: To determine oxidative stress biomarkers in HD patients and their relationship with clinical, demographic and neuroimaging parameters. DESIGN AND METHODS: Fourteen patients and 39 controls paired by age and sex participated in this study. Oxidative damage was assayed in blood by measuring malondialdehyde (MDA) and advanced oxidative protein products (AOPPs). Antioxidant status was determined by activities of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione reductase (GR), reduced glutathione (GSH), protein thiols and total antioxidant capacity (FRAP). The Unified Huntington Disease Rating Scale (UHDRS) and neuroimaging studies were also employed. RESULTS: MDA, AOPP and GPx were significantly increased in HD patients with respect to the control group, while GR activity was decreased. FRAP correlated with age of disease onset, AOPP with motor severity (UHDRS score), age of patients and age of disease onset. Caudate atrophy was associated with lower plasma concentrations of GSH. CONCLUSIONS: These findings point to a redox imbalance in HD patients. GR activity could be a potential biomarker for symptom onset in asymptomatic gene carriers, while plasmatic GSH could be useful in monitoring the progression of neurodegeneration - as an expression of caudate atrophy - during the course of the disease.


Subject(s)
Huntington Disease/blood , Huntington Disease/diagnosis , Adult , Age Factors , Age of Onset , Aged , Antioxidants/metabolism , Biomarkers/blood , Case-Control Studies , Catalase/blood , Caudate Nucleus/metabolism , Caudate Nucleus/pathology , Female , Glutathione/blood , Glutathione Peroxidase/blood , Glutathione Reductase/blood , Glycation End Products, Advanced/blood , Humans , Huntington Disease/diagnostic imaging , Huntington Disease/pathology , Male , Malondialdehyde/blood , Middle Aged , Oxidation-Reduction , Oxidative Stress , Sulfhydryl Compounds/blood , Superoxide Dismutase/blood , Tomography, X-Ray Computed
4.
Rev. cuba. invest. bioméd ; 8(1/2): 67-73, ene.-ago. 1989. tab
Article in Spanish | LILACS | ID: lil-81735

ABSTRACT

Se estudia el efecto del aerosol de queroseno sobre el metabolismo de los lìpidos en la rata. Se utilizaron ratas de las líneas Wister e INOR y recibieron tratamiento una hora diaria durante 30 días. Los controles recibieron aerosol de suero fisiológico en la misma forma. Se midieron los lípidos del plasma. Se extrajeron y cuantificaron los lípidos del pulmón, hígado y aorta. No se observaron diferencias significativas en las concentraciones de los lìpidos del plasma ni en las de los tejidos. Macroscópicamente no se observaron placas ateromatosas en las aortas. Los animales mostraron un decremento significativo de la ganancia de peso


Subject(s)
Rats , Animals , Aerosols , Kerosene/adverse effects , Lipids/metabolism
5.
Rev. cuba. invest. biomed ; 8(1-2): 67-73, ene.-ago. 1989. tab
Article in Spanish | CUMED | ID: cum-2371

ABSTRACT

Se estudia el efecto del aerosol de queroseno sobre el metabolismo de los lìpidos en la rata. Se utilizaron ratas de las líneas Wister e INOR y recibieron tratamiento una hora diaria durante 30 días. Los controles recibieron aerosol de suero fisiológico en la misma forma. Se midieron los lípidos del plasma. Se extrajeron y cuantificaron los lípidos del pulmón, hígado y aorta. No se observaron diferencias significativas en las concentraciones de los lìpidos del plasma ni en las de los tejidos. Macroscópicamente no se observaron placas ateromatosas en las aortas. Los animales mostraron un decremento significativo de la ganancia de peso


Subject(s)
Rats , Animals , Kerosene/adverse effects , Aerosols , Lipids/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...